Joel F Habener

This inventor holds 25 USPTO granted patents and 3 published patent applications and 3 EPO patents, primarily in Diabetes Treatment. Top assignees: The General Hospital Corporation, The United States of America, as Represented by the Secretary, Department of Health and Human Services, Viacell, Inc.. Active years: 1992-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Joel F Habener. Retrieved from https://idiyas.com/inventor/joel-f-habener

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 25 (Patent Applications = 3)

% Patents Active = 88.0

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 1.9

ph-index = 12

Forward Citations = 1,481(Granted Patents)

Location History:

Newton Highlands, MA (US) (1992 - 2006)
Newton, MA (US) (1992 - 2011)
Newton Centre, MA (US) (2001 - 2012)
Newton Center, MA (US) (2014 - 2018)

Company Filing History:

22 out of 3,079

The General Hospital Corporation

patents

1 out of 3,699

The United States of America, as Represented by the Secretary, Department of Health and Human Services

4. 1 out of 834,601

Other

patents

Years Active: 1992-2018

Loading Chart...

Areas of Expertise:

GLP-1

Insulin Production

Stem Cells

Diabetes Mellitus

Insulinotropic Hormones

Transcription Factors

C-Terminal Fragments

Pancreatic Disease

Immune Tolerance

Islets of Langerhans

Peptides

Disease Treatment

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10137171 - Methods of treatment using a pentapeptide derived from the C-Terminus of Glucagon-Like Peptide 1 (GLP-1) (2018-11-27),

2. 10118955 - C-terminal fragments of glucagon-like peptide-1 (GLP-1) (2018-11-06),

3. 9040481 - Methods for treating steatotic disease (2015-05-26),

4. 8889618 - C-terminal fragments of glucagon-like peptide-1 (GLP-1) (2014-11-18),

5. 8110399 - Stem cells of the islets of langerhans and their use in treating diabetes mellitus (2012-02-07),

6. 7875275 - Use of Bridge-1 and activators and inhibitors thereof in the treatment of insulin deficiency and diabetes (2011-01-25),

7. 7632812 - Methods to stimulate insulin production by pancreatic β-cells (2009-12-15),

8. 7544510 - Stem cells of the islets of Langerhans and their use in treating diabetes mellitus (2009-06-09),

9. 7138486 - Insulinotropic hormone derivatives and uses thereof (2006-11-21),

10. 7056734 - Differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or exendin-4 and uses thereof (2006-06-06),

11. 6923959 - Method of pre-inducing a state of immune tolerance before organ transplantation (2005-08-02),

12. 6903073 - Methods to stimulate insulin production by pancreatic beta-cells (2005-06-07),

13. 6866843 - Method of transplanting in a mammal and treating diabetes mellitus by administering a pseudo-islet like aggregate differentiated from a nestin-positive pancreatic stem cell (2005-03-15),

14. 6849708 - Insulinotropic hormone and uses thereof (2005-02-01),

15. 6274310 - Compositions and methods for detecting pancreatic disease (2001-08-14),

Title: The Innovative Journey of Joel F. Habener

Introduction: Joel F. Habener, a distinguished inventor hailing from Newton Centre, MA (US), has made significant contributions to the field of science and technology through his groundbreaking innovations.

Latest Patents: Joel F. Habener holds several patents in the areas of biotechnology and medical research, focusing on novel treatments for various diseases and disorders.

Career Highlights: With a career spanning several decades, Habener has established himself as a leading figure in the scientific community, known for his pioneering research and innovative solutions.

Collaborations: Throughout his career, Joel F. Habener has collaborated with top research institutions, universities, and biotech companies to further his research and bring his inventions to life.

Conclusion: Joel F. Habener's relentless pursuit of innovation and his passion for pushing the boundaries of scientific discovery have solidified his legacy as a visionary inventor in the field of biotechnology.

Profile summary based on public USPTO records.